Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is expected to issue its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Editas Medicine to post earnings of ($0.27) per share and revenue of $8.7680 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Editas Medicine Stock Up 11.6%

Editas Medicine stock opened at $2.11 on Wednesday. The firm has a market cap of $205.98 million, a P/E ratio of -0.89 and a beta of 2.15. The business has a fifty day moving average of $2.03 and a two-hundred day moving average of $2.61. Editas Medicine has a twelve month low of $0.91 and a twelve month high of $4.54.

Institutional Investors Weigh In On Editas Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its holdings in Editas Medicine by 138.0% in the fourth quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company’s stock worth $6,232,000 after acquiring an additional 1,762,378 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Editas Medicine by 122.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Editas Medicine by 761.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 800,023 shares of the company’s stock worth $2,776,000 after purchasing an additional 707,181 shares in the last quarter. Two Sigma Investments LP grew its position in Editas Medicine by 63.3% during the 3rd quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company’s stock worth $5,497,000 after purchasing an additional 614,229 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in Editas Medicine by 288.5% during the 1st quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock valued at $869,000 after purchasing an additional 558,567 shares in the last quarter. 71.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on EDIT shares. Weiss Ratings restated a “sell (e+)” rating on shares of Editas Medicine in a research note on Wednesday, January 21st. Chardan Capital raised shares of Editas Medicine from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 13th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $5.00.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.